SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending amid speculation around potential U.S. government investment in its Greenland rare earth project, driving significant price movement and high trading volume. Community discussions revolve around the validity of news reports, potential short squeezes, and the long-term prospects of the company given the increasing demand for rare earth minerals. Some traders believe this could reach new highs, while others are wary of potential volatility after initial reports of government interest faced pushback.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB is experiencing a surge in activity, with the community highlighting a significant gap up and multiple trading halts. Discussions revolve around the potential for further gains, comparisons to other high-flying stocks, and speculation about the reasons behind the sudden price movement, including potential connections to Wu Tang clan. Some traders caution about the risks associated with the volatility and the possibility of a correction.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending following news of a major deal with OpenAI, including a significant processor purchase and potential equity stake, sending the stock soaring. Community discussions revolve around the deal's implications for AMD's competition with Nvidia and the broader AI chip market. Some are skeptical, questioning the financial dynamics of the agreement, while others see it as a validation of AMD's technology and growth potential.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid speculation about a potential partnership with Tesla, fueled by a teaser video and upcoming announcements. Community discussions revolve around the possibility of autonomous flight integration and the potential impact on the eVTOL market, with some traders expressing high bullish sentiment and anticipating a significant breakout. The stock's recent price surge and high trading volume indicate increased investor interest in Archer's future prospects within the electric vertical takeoff and landing (eVTOL) industry.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is currently trending with community members actively discussing potential breakouts and key resistance levels, as well as corporate accumulation. There is excitement around new projects launching on the Solana blockchain and bullish sentiment fueled by talk of possible ETF approvals and the potential impact on institutional investment. The community also mentions other tokens within the Solana ecosystem.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending due to ongoing discussions around quantum computing's potential and its role in energy efficiency, particularly within data centers. Community members are debating the stock's valuation, comparing it to peers like IONQ and RGTI, while also weighing its long-term potential against short-term risks and potential pullbacks. Some traders are taking profits, while others remain bullish, citing positive technical analysis and potential catalysts like government contracts.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma ($FIG) is trending amid discussions about its availability within ChatGPT apps and a recent spike in price, with some speculating about potential integration announcements. The community is actively debating the reasons behind the move, including potential short squeezes and the impact of a recent DEVDAY. Some investors are optimistic about the company's long-term potential, while others express concerns about lockup periods and potential trapping of retail investors.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express bullish sentiment and highlight its strong, active community. Talk centers around the token's potential, particularly within the Solana ecosystem and the Pump.fun platform. The community emphasizes long-term conviction and organic growth.

Pump.fun

Pump.fun ($PUMP) is trending as traders discuss its potential for significant gains, especially within the Solana ($SOL) meme coin ecosystem. Community members are focused on the "We're All Gonna Make It" ($WAGMI) narrative and touting the strength and positivity of the $WAGMI community, with some anticipating major CEX listings soon. Others highlight the platform's buyback program and creator rewards, while some traders express concerns about excessive shilling.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a mix of bullish sentiment and skepticism surrounding its valuation within the quantum computing sector; the community is actively debating whether the stock's impressive gains are justified, with some highlighting potential overvaluation and an imminent offering, while others emphasize the company's technology and future potential. Discussions also include comparisons to other quantum computing stocks and established tech companies, as well as observations on short selling activity.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why

Phathom Pharmaceuticals (PHAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?

The mean of analysts' price targets for Phathom Pharmaceuticals (PHAT) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet

The consensus price target hints at an 87.2% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -3.95% and +8.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MannKind (MNKD) Reports Break-Even Earnings for Q2

MannKind (MNKD) delivered earnings and revenue surprises of -100.00% and -2.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates

Krystal Biotech (KRYS) delivered earnings and revenue surprises of +19.44% and +6.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade

Phathom Pharmaceuticals shares soar on FDA exclusivity grant

Investing.com -- Shares of Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) soared 128% after the FDA granted the company’s petition for exclusivity in the Orange Book listing for its drug Voquezna (vonoprazan fumarate). The decision by the Food and Drug Administration to extend the exclusivity period to a full 10 years for Voquezna, under the umbrella of the Generating Antibiotic Incentives Now (GAIN) provisions, has been a significant catalyst for the stock’s movement.

​Retail interest for Phathom Pharmaceuticals soared on Thursday after the company reported first-quarter results, unveiled a sweeping cost-reduction plan and reaffirmed its target to achieve operational profitability by 2026.The company posted Q1 revenue of $28.5 million, slightly below the $29.02 million consensus.&nbsp;Its net loss widened to $94.3 million from $82.9 million a year earlier, driven largely by increased advertising and promotional spend for its lead drug, VOQUEZNA.“2025 will be an inflection point for Phathom,” said CEO Steve Basta.&nbsp;The company announced a 6% workforce reduction, multiple leadership changes, and significant cuts in external spending.&nbsp;Phathom expects the moves to reduce 2025 operating expenses by $60 million to $70 million and lower quarterly spend to under $55 million by the fourth quarter.Basta said the company’s actions are designed to support long-term growth without raising new equity or debt. He added that sales force strength remains a top priority, with commercial personnel now comprising around 75% of the total workforce.Voquezna prescriptions rose 8% sequentially in Q1 to 127,000, while cumulative prescriptions surpassed 390,000 as of April 18.&nbsp;Commercial access remained strong, with coverage extending to over 120 million lives, including more than 80% of commercially insured patients.Phathom also paused its planned Phase 2 trial for eosinophilic esophagitis and is awaiting an FDA decision on its citizen petition seeking full NCE exclusivity through 2032.Retail traders on Stocktwits remained optimistic despite the revenue miss, with sentiment marked as ‘bullish’ amid a 900% surge in 24-hour messaging volume.&nbsp;Several users said they were buying the dip, expressing continued confidence in the company’s long-term prospects.<stembedurl>https://stocktwits.com/DrDare/message/613236534</stembedurl>One user said the volume spike was notable but still lower than on days when major patent or executive updates had occurred.&nbsp;<stembedurl>https://stocktwits.com/Morrito23/message/613282417</stembedurl>They noted persistent concerns over cash burn, but said they welcomed management's move to finally address the issue publicly.Some traders described the first quarter as unusually difficult for pharmaceutical firms, citing formulary changes and deductible resets.&nbsp;Others saw the update as a turning point, with one saying the stock could become a buyout candidate if exclusivity concerns are resolved and revenue momentum continues.<stembedurl>https://stocktwits.com/Canvasback33/message/613238887</stembedurl>Shares of Phanthom have fallen 54.2% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Packaging and pills of different types of psychotropic medications are seen in this illustration photo taken in Warsaw, Poland on 22 April, 2025. (Photo by Jaap Arriens/NurPhoto via Getty Images)

Retail Interest in Phathom Soars As Firm Pledges Profit Path, Cuts Costs After Q1 Miss

Phathom's VOQUEZNA prescriptions rose 8% sequentially in Q1, with over 390,000 cumulative fills and expanding adoption across both GI and primary care. 

Equity

Phathom's Voquezna prescriptions rose 8% sequentially in Q1, with over 390,000 cumulative fills and expanding adoption across both GI and primary care. 


2 Growth Stocks to Buy Now With 367% to 410% Upside

Strong, innovative pipelines make these two biotech firms smart buys now.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

PHAT
Phathom Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PHAT News

PHAT Phathom Pharmaceuticals Inc